Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

Beneficial effect of TLR4 blockade by a specific aptamer antagonist after acute myocardial infarction

  • Paz-García, Marta
  • Hernández Jiménez, Macarena
  • Moro Sánchez, María Ángeles
  • Lizasoaín Hernández, Ignacio
  • Valenzuela, Carmen et al.
  • Prieto Chinchilla, Patricia
  • Bosca Gomar, Lisardo
Experimental evidence indicates that the control of the inflammatory response after myocardial infarction is a key strategy to reduce cardiac injury. Cellular damage after blood flow restoration in the heart promotes sterile inflammation through the release of molecules that activate pattern recognition receptors, among which TLR4 is the most prominent. Transient regulation of TLR4 activity has been considered one of the potential therapeutic interventions with greater projection towards the clinic. In this regard, the characterization of an aptamer (4FT) that acts as a selective antagonist for human TLR4 has been investigated in isolated macrophages from different species and in a rat model of cardiac ischemia/reperfusion (I/R). The binding kinetics and biological responses of murine and human macrophages treated with 4FT show great affinity and significant inhibition of TLR4 signaling including the NF-κB pathway and the LPS-dependent increase in the plasma membrane currents (Kv currents). In the rat model of I/R, administration of 4FT following reoxygenation shows amelioration of cardiac injury function and markers, a process that is significantly enhanced when the second dose of 4FT is administered 24 h after reperfusion of the heart. Parameters such as cardiac injury biomarkers, infiltration of circulating inflammatory cells, and the expression of genes associated with the inflammatory onset are significantly reduced. In addition, the expression of anti-inflammatory genes, such as IL-10, and pro-resolution molecules, such as resolvin D1 are enhanced after 4FT administration. These results indicate that targeting TLR4 with 4FT offers new therapeutic opportunities to prevent cardiac dysfunction after infarction.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

NOD1 activation in cardiac fibroblasts induces myocardial fibrosis in a murine model of type 2 diabetes

  • Val-Blasco, Almudena
  • Prieto, Patricia
  • González-Ramos, Silvia
  • Benito, Gemma
  • González-Peramato, Pilar
  • Agra, Noelia
  • Terrón, Verónica
  • Delgado, Carmen
  • Martín-Sanz, Paloma
  • Boscá, Lisardo
  • Fernández-Velasco, María
Cardiac fibrosis and chronic inflammation are common complications in type 2 diabetes mellitus (T2D). Since nucleotide oligomerization-binding domain 1 (NOD1), an innate immune receptor, is involved in the pathogenesis of insulin resistance and diabetes outcomes, we sought to investigate its involvement in cardiac fibrosis. Here, we show that selective staining of cardiac fibroblasts from T2D (db/db;db) mice exhibits up-regulation and activation of the NOD1 pathway, resulting in enhanced NF-κB and TGF-β signalling. Activation of the TGF-β pathway in cardiac fibroblasts from db mice was prevented after inhibition of NF-κB with BAY-11-7082 (BAY). Moreover, fibrosis progression in db mice was also prevented by BAY treatment. Enhanced TGF-β signalling and cardiac fibrosis of db mice was dependent, at least in part, on the sequential activation of NOD1 and NF-κB since treatment of db mice with a selective NOD1 agonist induced activation of the TGF-β pathway, but co-administration of a NOD1 agonist plus BAY, or a NOD1 inhibitor prevented the NOD1-induced fibrosis. Therefore, NOD1 is involved in cardiac fibrosis associated with diabetes, and establishes a new mechanism for the development of heart fibrosis linked to T2D., M.F.-V. is a Miguel Servet researcher of the ISCIII. This work was supported by grants [SAF2014-52492R] and [RTC2015-3741] from MINECO; [CP11/00080] and [PI14/01078] from ISCIII, FEDER (Fondo Europeo de Desarrollo Regional) and RIC (Red de Investigación Cardiovascular) [RD12/0042/0019]. RIC is a network funded by the Carlos III Health Institute (ISCIII)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Role of NOD1 in heart failure progression via regulation of Ca2+ handling

  • Val-Blasco, Almudena
  • Ruiz-Hurtado, Gema
  • Prieto, Patricia
  • González-Ramos, Silvia
  • Gómez-Hurtado, Nieves
  • Delgado, Carmen
  • Benito, Gemma
  • Zaragoza, Carlos
  • López-Collazo, Eduardo
  • Boscá, Lisardo
  • Fernández-Velasco, María
[Background]: Heart failure (HF) is a complex syndrome associated with a maladaptive innate immune system response that leads to deleterious cardiac remodeling. However, the underlying mechanisms of this syndrome are poorly understood. Nucleotide-binding oligomerization domain-containing protein 1 (NOD1) is a newly recognized innate immune sensor involved in cardiovascular diseases. [Objectives]: This study evaluated the role of NOD1 in HF progression. [Methods]: NOD1 was examined in human failing myocardium and in a post-myocardial infarction (PMI) HF model evaluated in wild-type (wt-PMI) and Nod1 mice (Nod1-PMI). [Results]: The NOD1 pathway was up-regulated in human and murine failing myocardia. Compared with wt-PMI, hearts from Nod1-PMI mice had better cardiac function and attenuated structural remodeling. Ameliorated cardiac function in Nod1-PMI mice was associated with prevention of Ca dynamic impairment linked to HF, including smaller and longer intracellular Ca concentration transients and a lesser sarcoplasmic reticulum Ca load due to a down-regulation of the sarcoplasmic reticulum Ca-adenosine triphosphatase pump and by augmented levels of the Na/Ca exchanger. Increased diastolic Ca release in wt-PMI cardiomyocytes was related to hyperphosphorylation of ryanodine receptors, which was blunted in Nod1-PMI cardiomyocytes. Pharmacological blockade of NOD1 also prevented Ca mishandling in wt-PMI mice. Nod1-PMI mice showed significantly fewer ventricular arrhythmias and lower mortality after isoproterenol administration. These effects were associated with lower aberrant systolic Ca release and with a prevention of the hyperphosphorylation of ryanodine receptors under isoproterenol administration in Nod1-PMI mice. [Conclusions]: NOD1 modulated intracellular Ca mishandling in HF, emerging as a new target for HF therapy., This work was supported by grants CP11/00080 and PI14/01078 from Instituto de Salud Carlos III (ISCIII); SAF2014-52492-R, SAF2014-57190-R, and RTC2015-3741 from Ministerio de Economía y Competitividad; Fondos Fondo Europeo de Desarrollo Regional; and Red de Investigación Cardiovascular (RIC) RD12/0042/0019. RIC is a network funded by the Carlos III Health Institute. Dr. Fernández Velasco is Miguel Servet researcher of ISCIII., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Beneficial effect of TLR4 blockade by a specific aptamer antagonist after acute myocardial infarction

  • Paz-García, Marta
  • Povo-Retana, Adrián
  • Jaén, Rafael I.
  • Prieto, Patricia
  • Peraza, Diego A.
  • Zaragoza, Carlos
  • Hernández-Jiménez, M.
  • Pineiro, David
  • Regadera, Javier
  • García-Bermejo, María Laura
  • Rodríguez-Serrano, Macarena
  • Sánchez-García, Sergio
  • Moro, María A.
  • Lizasoain, Ignacio
  • Delgado, Carmen
  • Valenzuela, Carmen
  • Boscá, Lisardo
Experimental evidence indicates that the control of the inflammatory response after myocardial infarction is a key strategy to reduce cardiac injury. Cellular damage after blood flow restoration in the heart promotes sterile inflammation through the release of molecules that activate pattern recognition receptors, among which TLR4 is the most prominent. Transient regulation of TLR4 activity has been considered one of the potential therapeutic interventions with greater projection towards the clinic. In this regard, the characterization of an aptamer (4FT) that acts as a selective antagonist for human TLR4 has been investigated in isolated macrophages from different species and in a rat model of cardiac ischemia/reperfusion (I/R). The binding kinetics and biological responses of murine and human macrophages treated with 4FT show great affinity and significant inhibition of TLR4 signaling including the NF-κB pathway and the LPS-dependent increase in the plasma membrane currents (Kv currents). In the rat model of I/R, administration of 4FT following reoxygenation shows amelioration of cardiac injury function and markers, a process that is significantly enhanced when the second dose of 4FT is administered 24 h after reperfusion of the heart. Parameters such as cardiac injury biomarkers, infiltration of circulating inflammatory cells, and the expression of genes associated with the inflammatory onset are significantly reduced. In addition, the expression of anti-inflammatory genes, such as IL-10, and pro-resolution molecules, such as resolvin D1 are enhanced after 4FT administration. These results indicate that targeting TLR4 with 4FT offers new therapeutic opportunities to prevent cardiac dysfunction after infarction., This work has been supported by: Ministerio de Ciencia, Investigación y Universidades, Agencia Estatal de Investigación 10.13039/501100011033 (PID2020-113238RB-I00; PID2019-106581RB-I00), RETOS-Colaboración (RTC-2015-3741-1), RETOS-Colaboración (RTC-2017-6651-1), Centro para el Desarrollo Tecnológico Industrial (Neotec Program, EXP-00104980, SNEO-2017115); PI20/00535, RICORS RD21/0006/0001 and Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CB16/11/00222) from the Instituto de Salud Carlos III (co-financed by the European Development Regional Fund “A Way to Achieve Europe”); Comunidad de Madrid Programa Biociencias (P2022-BMD-7223); and Leducq Foundation for Cardiovascular Research TNE-19CVD01 and TNE21CVD04., Peer reviewed